240 patients who had neuropathic pain that was associated with multiple sclerosis (MS) were randomly assigned to receive either dronabinol 7.5-15.0 mg daily for 16 weeks, or its respective placebo with the identical schedule. No significant differences in pain reduction and quality of life improvement were found in patients that received dronabinol compared to those that received placebo. In a following open-label period, 100 patients received dronabinol for 32 weeks and had pain reduction. Most patients assessed the global tolerability to be good or very good. One patient showed mild signs of drug dependency. No patients had signs of drug abuse.